Pancreatic Cell News Volume 13.20 | May 24 2022

    By
    Bob
    -
    0
    41







    2022-05-24 | PACN 13.20


    Pancreatic Cell News by STEMCELL Technologies
    Vol. 13.20 – 24 May, 2022
    TOP STORY

    Hesperadin Suppresses Pancreatic Cancer through ATF4/GADD45A Axis at Nanomolar Concentrations

    Scientists identified Hesperadin as a potent anti-cancer compound against pancreatic cancer, from a high-throughput screening of a commercial chemical library associated with cell death.
    [Oncogene]

    Abstract
    Tips to prepare for your next conference or networking event
    PUBLICATIONSRanked by the impact factor of the journal

    NF-κB-Inducing Kinase (NIK) Is Activated in Pancreatic β-Cells but Does Not Contribute to the Development of Diabetes

    Investigators showed that genetic silencing of NIK in pancreatic β-cells neither modified diabetes incidence nor inflammatory responses in a mouse model of immune-mediated diabetes.
    [Cell Death & Disease]

    Full Article

    A Saponin from Astragalus Promotes Pancreatic Ductal Organoids Differentiation into Insulin-Producing Cells

    The authors established mouse pancreatic ductal organoids with progenitor characteristics and an insulin promoter-driven enhanced green fluorescent protein reporter system to screen astragalus saponin components for monomers that could promote insulin-producing cell differentiation.
    [Phytomedicine]

    AbstractGraphical Abstract

    Ginsenoside Rg3 Ameliorates Acute Pancreatitis by Activating the NRF2/HO-1-Mediated Ferroptosis Pathway

    An in vitro acute pancreatitis cell model was established in the present study by exposing AR42J cells to cerulein (Cn). AR42J cell viability was increased in the Rg3‑treated group as compared with the Cn‑exposed group.
    [International Journal of Molecular Medicine]

    Abstract

    NNK from Tobacco Smoking Enhances Pancreatic Cancer Cell Stemness and Chemoresistance by Creating a β2AR-Akt Feedback Loop That Activates Autophagy

    The authors found that 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) promoted stemness and gemcitabine resistance in pancreatic cancer cell lines.
    [Molecular Oncology]

    AbstractFull Article

    Transcriptional ITPR3 as Potential Targets and Biomarkers for Human Pancreatic Cancer

    Researchers examined the expression levels and survival dates of Inositol 1,4,5-Triphosphate Receptor Family (ITPRs) in patients with pancreatic cancer. As a result, they identified that ITPR1 and ITPR3 expression levels were significantly elevated in cancerous specimens.
    [Aging]

    Full Article

    Butyrate, a Postbiotic of Intestinal Bacteria, Affects Pancreatic Cancer and Gemcitabine Response in In Vitro and In Vivo Models

    Scientists provided in vitro evidence that, in addition to slowing proliferation, butyrate enhanced gemcitabine effectiveness against two human pancreatic cancer cell lines, mainly inducing apoptosis.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids

    Investigators provided a systematic evaluation of photodynamic therapy in 3D heterotypic coculture models of PDAC with varying ratios of patient-derived pancreatic cancer-associated fibroblasts that simulated heterogeneous PDAC tumors with increasing stromal content.
    [Molecular Pharmaceutics]

    AbstractGraphical Abstract

    Sparstolonin B Inhibits Pancreatic Adenocarcinoma through the NF-κB Signaling Pathway

    Sparstolonin B significantly decreased Panc-1 and SW1990 cell viability and effectively suppressed the proliferation, migration, and invasion of pancreatic cancer cells as shown by CCK-8, colony formation, and Transwell assays.
    [Experimental Cell Research]

    Abstract
    Subscribe to Science News for free weekly science newsletters.
    REVIEWS

    Nanoparticle-Based Therapeutic Strategies Targeting Major Clinical Challenges in Pancreatic Cancer Treatment

    The authors focus on the pathological hallmarks of PDAC and the impact of nanotechnology to find solutions, describing the use of nanoparticle-based systems designed for the delivery of chemotherapeutic agents and combinatorial alternatives that address the chemoresistance associated with PDAC.
    [Advanced Drug Delivery Reviews]

    AbstractGraphical Abstract

    Exosomes and Their Roles in the Chemoresistance of Pancreatic Cancer

    Investigators focus on the intrinsic connections between the chemoresistance of pancreatic cancer cells and exosomes in the tumor microenvironment.
    [Cancer Medicine]

    Full Article
    INDUSTRY AND POLICY NEWS

    PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

    PharmaCyte Biotech, Inc. announced that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites.
    [PharmaCyte Biotech, Inc.]

    Press Release
    FEATURED EVENT

    3D Cell Culture Symposium

    13 – 14 September 2022

    London, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Tenure Track Scientist – Metabolism

    Rutgers Robert Wood Johnson Medical School – New Brunswick, New Jersey, United States

    Lab Associate – Human Islet Isolation

    City of Hope – Duarte, California, United States

    Research Associate I – Epigenetic Regulation of Pancreatic Beta-Cell Mass

    City of Hope – Duarte, California, United States

    Principal Investigator – Interdisciplinary Research in Biology

    CNRS – Paris, France

    Postdoctoral Position – Clinical Proteomics

    Steno Diabetes Center – Herlev, Denmark

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pancreatic Cell News Twitter